Teresa Evering, MD, MS

Teresa Evering Dr. Evering is an Associate Attending Physician at the Rockefeller University Hospital and Assistant Professor of Clinical Investigation at the Aaron Diamond AIDS Research Center (ADARC). Dr. Evering received her MD from the Weill Cornell Medical College, continued her training as a resident in Internal Medicine at New York-Presbyterian Hospital - Columbia University Medical Center and trained as an Infectious Diseases Fellow at the Albert Einstein College of Medicine/Montefiore Medical Center.

Dr. Evering joined the Rockefeller University Clinical Scholars program under the mentorship of Dr. Martin Markowitz, the Clinical Director of ADARC in July 2007. During her time as a Clinical Scholar, Dr. Evering's research focused on important questions surrounding the potential for ongoing viral replication during suppressive combination antiretroviral therapy (cART) for the human immunodeficiency virus-1 (HIV-1). Prior to her June 2010 graduation with a Rockefeller University Center for Clinical and Translational Science Master's degree, she was awarded a NIH Clinical Scientist Research Career Development Award (K08) under the mentorship of Dr. David Ho and Dr. Martin Markowitz.

Supported by the NIH, her current research is focused on the study of HIV-1-associated neurocognitive disorders (HAND). Penetration of the central nervous system (CNS) by HIV-1 occurs early in infection, and can result in a wide range of pathological and clinical manifestations - all of which can contribute significantly to morbidity and mortality. The widespread use of cART has led to a clear reduction in the incidence of HIV-associated dementia (HAD), one of the most severe manifestations of HIV-1 CNS infection. Nonetheless, HANDs persist in the cART era and are a pervasive and debilitating potential clinical complication of infection with HIV-1. Using HIV-1 variants sequenced from the cerebrospinal fluid (CSF) and plasma of participants in the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study, Dr. Evering is working to elucidate HIV-1 CNS evolutionary pathways and explore genetic determinants of neurotropism, neuroinvasiveness and neurovirulence through an in-depth, integrated, phylogenetic and functional approach. Additional funding from a Rockefeller University Clinical and Translational Science Award (CTSA) pilot grant has allowed her to complement this work with a clinical study investigating the prevalence and clinical impact of HAND in individuals treated with early cART. Dr. Evering is also a co-investigator on a number of clinical studies investigating HIV-1 pathogenesis, and agents for treatment and prevention at ADARC/RU.

Board certified in Internal Medicine and Infectious Diseases, Dr. Evering has served as the Chair of the Infection Prevention & Control & Blood Products Committee at the Rockefeller University Hospital since 2008 and is the Community Engagement Scientific Liaison for the Rockefeller University Center for Clinical and Translational Science (CCTS).

Publications:

Evering TH, Kamau E, St Bernard L, Farmer CB, Kong XP, Markowitz M. Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope. Retrovirology. 2014 Aug 15;11(1):65. PMCID: PMC4145222.

Markowitz M, Evering TH, Garmon D, Caskey M, La Mar M, Rodriguez K, Sahi V, Palmer S, Prada N, Mohri H. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):140-7. PMCID: PMC4123437.

Castor D, Low A, Evering T, Karmon S, Davis B, Figueroa A, LaMar M, Garmon D, Mehandru S, Markowitz M. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr. 2012 2012 Sep 1;61(1):1-8. PubMed PMID: PMC3427460

Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012 Feb;8(2):e1002506. PubMed PMID: PMC3271083

Evering TH, Markowitz M. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs. 2008 Mar;17(3):413-22. Review. PubMed PMID: 18321239.

Evering TH, Markowitz M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today (Barc). 2007 Dec;43(12):865-77. Review. PubMed PMID: 18174972.

Muehlbauer SM, Evering TH, Bonuccelli G, Squires RC, Ashton AW, Porcelli SA, Lisanti MP, Brojatsch J. Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis. Cell Cycle. 2007 Mar 15;6(6):758-66. Epub 2007 Mar 7. PubMed PMID: 17374996.

Derrick SC*, Evering TH*, Sambandamurthy VK, Jalapathy KV, Hsu T, Chen B, Chen M, Russell RG, Junqueira-Kipnis AP, Orme IM, Porcelli SA, Jacobs WR Jr, Morris SL. Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology. 2007 Feb;120(2):192-206. Epub 2006 Oct 31. PubMed PMID: 17076705; PubMed Central PMCID: PMC2265854. *Equal Contribution

Evering T, Weiss LM. The immunology of parasite infections in immunocompromised hosts. Parasite Immunol. 2006 Nov;28(11):549-65. Review. PubMed PMID: PMC3109637.

Book Chapters:

Markowitz M, Evering TH. Raltegravir and Other HIV Integrase Inhibitors. In Grayson ML (Chief Ed.), Kucers' The Use of Antibiotics (6th ed.). London: Hodder Arnold. 2010.